"The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.

Priority Review designation is used for treatments that address a serious or life-threatening disease or condition

"One young man is on a mission to gather as many power chords as possible for children who are hospitalized.

It's called Power Jacks, which only makes sense because it was created by 13 year-old Jack Lewy.

Lewy is no stranger to Tulane Lakeside Hosptial for Women and Children in Metairie.

In December, Lewy suffered

"Novartis Korea said Tuesday additional data analysis from its EXTEND clinical trial for Revolade (ingredient: eltrombopag) proved it safe and effective for those 65 years and older with idiopathic thrombocytopenic purpura (ITP).

The sub-set study findings were presented at the first International Congress of BMT symposium held in Seoul on Aug. 26.

Revolade (known as

"Protalex, Inc., a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the second dose cohort of its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study), the Company has initiated enrollment in the third cohort of this dose-escalating study. The first patient in